Baheal Pharma GroupH6.B76Baheal Pharma Group is a health industry leader driven by scientific and technological innovations. With robust industrialization capabilities and a focus on asset accretion, the Group excels in the incubation of medical innovations.
Drawing on deep clinical insights, Baheal has established a platform to transform scientific research into practical applications. Collaborating with top national research institutes to explore original innovations that can optimize medical scenarios. The emphasis lies on pioneering accomplishments with potential as First-in-Class and “Key & Core Technology” for investment and incubation. As an industry investor, Baheal leverages industry funds to concentrate on three major value accretion tracks such as innovative medicines, high-end medical devices, and basic research platforms, by providing funding, technology transformation support, marketing, and other resource allocations to nurture innovative medical and health products with exclusive intellectual property.
Furthermore, Baheal has built a pharmaceutical industrialization platform (Baheal Medical, stock code: 301015) to support original innovation. By focusing on professional product development,
manufacturing, and commercialization of health brands, Baheal accelerates the integration of medical innovation into clinical practices. Through technological innovation, it enhances the overall efficiency and quality of medical services. Currently, Baheal has launched several innovative traditional Chinese and chemical medicines with strong independent intellectual property rights. It has incubated multiple leading brands in the fields of bone health, liver disease, metabolic disorders, etc., with a marketing network covering over 14,000 large and medium-sized hospitals and 400,000 pharmacies.
Baheal Pharma Group will continue to adhere to the strategic path of “Branding, Innovation, and Globalization,” providing better medical health products and services to the whole society.
